Teva launches generic Campral

JERUSALEM — Teva Pharmaceuticals on Tuesday announced the launch of its Campral (acamprosate calcium) delayed-release tablets. The drug is indicated to help maintain abstinence from alcohol dependence in patients who are abstinent when treatment begins, alongside a treatment program including counseling and support. 

 

The drug will be available in 333-mg dosage strength, and had annual sales of about $14 million for the 12 months ended December 2015, according to IMS Health.